Press

Irwin Naturals Reports Year End 2022 Financial Results and Recent Events

May 26 • 4 min read

Irwin Naturals Inc. (CSE: IWIN / OTC: IWINF / FRA: 97X) today reported its financial results for the fourth quarter and year ended December 31, 2022, on www.sedar.com. Financial Highlights for FY 2022 (all comparisons are for the year ended December 31 unless otherwise indicated): Financial Highlights for Q4 2022 and Year to Date 2023 Operational Highlights…

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)

May 26 • 3 min read

Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces data from a long-term, 18-month follow-up study of psilocybin therapy in cancer patients with MDD, at the Annual Meeting of the American Society of Clinical Oncology (ASCO). This is believed to be the…

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

May 26 • 4 min read

Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP“) portfolio, demonstrating significant progress already made by the Company in 2023. Small Pharma aims to protect its pipeline programs through a multi-layered IP strategy with four…

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

May 26 • 4 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy (“MDMA-AT”) in the United States in the first half of 2024. In anticipation of this regulatory…

MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use

May 23 • 2 min read

The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of the Global Psychedelic Survey. Co-sponsored by MAPS, SABI Mind, Mind Medicine Australia, and Tiny, the survey marks the most comprehensive assessment of psychedelic use amongst adults to date. In keeping with the spirit of community-based research and harm reduction, the Global Psychedelic Survey provides English-speaking adults from…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441